Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1146

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: Eluxadoline
DRUG: Placebo

Sponsor

Furiex Pharmaceuticals, Inc